Study Summary:
This is a 52-week double blind, placebo controlled trial to evaluate the efficacy, safety and tolerability of a new study drug in patients with COPD.
Qualified Participants Must:
• Be 40 years of age or older
•
Have moderate to severe COPD
•
Have a smoking history
Qualified Participants May Receive:
Compensation for time and travel as well as study related medication and medical care including lab work and physicals.